Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes

Pan, Jiehong; Van, Joanne T.; Chan, Eve; Kesala, Renata L.; Lin, Michael K.; Charles, M. Arthur

doi:10.1053/meta.2002.34701

Cited by 51 publications

(24 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other drugs such as acetylsalicylic acid and L-carnitine can decrease mildly elevated Lp(a) concentrations (91,93,94). Contradictory findings have been reported with statins (95)(96)(97)(98). Promising molecules like mipomersen, an antisense oligonucleotide directed to human apoB 100 have been shown to reduce Lp(a) concentrations by 70% in transgenic mice (99).…”

Section: Treatmentmentioning

confidence: 98%

Lipoprotein (a) and Cardiovascular Risk

Peromingo¹

2012

Recent Advances in Cardiovascular Risk Factors

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 98%

Lipoprotein (a) and Cardiovascular Risk

Peromingo¹

2012

Recent Advances in Cardiovascular Risk Factors

View full text Add to dashboard Cite

“…A beneficial effect on LDL particle distribution in patients with type 2 diabetes could be shown in two studies using final dosages of niacin of 1-4 g per day [78,79].…”

Section: Lipid Lowering Agents Targeting Ldl Particle Distributionmentioning

confidence: 99%

Small dense low-density lipoprotein particles: priority as a treatment target in Type 2 diabetes?

Gerber¹,

Spinas²,

Berneis³

2012

Diabetes Management

View full text Add to dashboard Cite

During the past two decades, the importance of the quality of low-density lipoprotein (LDL) particles -in addition to its quantity -has become of increasing interest. The risk of cardiovascular events was recognized to be closely linked to a predominance of small, dense LDL particles. In addition, in patients with Type 2 diabetes mellitus, the disease itself and its severity (in particular the degree of insulin resistance) is associated with this subclass of LDL particles. Lipid lowering as well as antihyperglycemic drugs have been evaluated in many studies concerning their effect on LDL particle size. It has increasingly been recognized that a reduction of LDL quantity is not necessarily associated with a beneficial effect on LDL quality. Advances in the understanding of alterations in LDL quality may therefore influence the choice of the therapeutic regimen in patients with diabetes in the future. SummaryDuring the last two decades, the importance of the quality of low-density lipoprotein (LDL) particles -in addition to its quantity -has become of increasing interest. The risk of cardiovascular events was recognized to be closely linked to a predominance of small, dense LDL particles. In addition, in patients with type 2 diabetes mellitus, the disease itself and its severity (in particular the degree of insulin resistance) is associated with this subclass of LDL particles. Lipid lowering as well as antihyperglycemic drugs have been evaluated in many studies concerning their effect on LDL particle size. It has increasingly been recognized that a reduction of LDL quantity is not necessarily associated with a beneficial effect on LDL quality. Advances in the understanding of alterations in LDL quality may therefore influence the choice of the therapeutic regimen in patients with diabetes in the future.

show abstract

“…The ER formulation was used in doses of 1 to 3 g/d, with significantly reduced adverse effects. 7 Pan et al 15 reported that ERN is effective in Lp(a) reduction even in the treatment of diabetic dyslipidemias, independently of A1C levels. In the COMPELL study, where 4 treatment regiments were tested, the statin/ERN combination lead to an ∼40% reduction of Lp(a), with negligible adverse effects.…”

Section: 12-14mentioning

confidence: 99%

“…16 Effective Lp(a) lowering may be dependent on the type of lipid abnormalities associated with high Lp(a), the dose of niacin, type of formulation, time of treatment, and so on. 2,7,12,13,15 The effect of niacin on cardiovascular outcomes is uncertain. The HPS2-THRIVE trial found an increased risk of myopathy, diabetes, and increased ALT, without CVD risk reduction, when 2 g of ERN/LRPT[AQ6] were added to statin therapy, despite its beneficial effect on LP fractions (Lp(a) was not a subject of analysis in this study).…”

Section: 12-14mentioning

confidence: 99%

Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a)

et al. 2016

View full text Add to dashboard Cite

Please confirm you have reviewed this proof to your satisfaction and understand this is your final opportunity for review prior to publication.Please confirm that the Funding and Conflict of Interest statements are accurate. AQ 1Please shorten the abstract, so that it does not exceed 250 words A total of 87 patients, 61 ± 12 years old, were analyzed. The main risk factors were obesity (64.7%) and hypertension (64.6%). Men were more often smokers (odds ratio [OR] = 5.1) and had CAD (OR = 2.8), but lower total C (206.9 ± 32.9 vs 238.6 ± 47.9 mg/dL, P = 0.002) and LDL-C (136.5 ± 18.2 vs 160.9 ± 30.9 mg/dL, P = 0.000). Mean Lp(a) was 94.6 ± 39.6 mg/dL, without significant gender difference. There were 25 patients in the R group, 22 in the A group, and 20 each in the A+F and A+ERN groups. Significant reduction in all lipid fractions in all treatment groups was reported after 6 months. The average reduction of Lp(a) was 15.9 ± 21.0 mg/dL, with 18.2 ± 24.8 (P = 0.001) in the R group and similar values in the A+F and A+ERN groups (17.3 ± 10.4, P = 0.001, and 19.5 ± 10.9, P = 0.001, respectively), and the lowest in the A group (11.24 ± 22.91, P = 0.032). No adverse effects were observed in any of the treatment groups. Conclusions: When compared with atorvastatin, it seems that rosuvastatin can achieve a statistically more significant decrease of Lp(a). The efficacy of atorvastatin on the Lp(a) optimization can be increased by adding either fibrate or ERN. Given in recommended doses, all agents were well tolerated.[AQ1]

show abstract

Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes

Cited by 51 publications

References 45 publications

Lipoprotein (a) and Cardiovascular Risk

Lipoprotein (a) and Cardiovascular Risk

Small dense low-density lipoprotein particles: priority as a treatment target in Type 2 diabetes?

Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a)

Contact Info

Product

Resources

About